We would like to inform you that we have completed the first part of the study with a single, escalating dose (FIH, SAD) (Part A), of the innovative antidiabetic drug.

 

We would like to inform you that we have completed the first part of the study with a single, escalating dose (FIH, SAD) (Part A), of the innovative antidiabetic drug. The project was implemented in cooperation with a Polish pharmaceutical company. The new therapy aims to reduce insulin resistance and to regulate the chronic high blood glucose level. Due to the state of the pandemic, the study was conducted in accordance with the highest sanitary standards as well as procedures related to the monitoring of the epidemic state. This approach, combined with the principles of GCP, ensured the safety and well-being of our patients. Soon we are starting the second part of the study (hello B0) with multiple, escalating dose of the new drug.

Go back

News

Easter Wishes

To all our Sponsors, Vendors, Employees and Co-Workers we wish joy and happiness for the in-coming Easter!

Read more …

Annual GCP training

On 24th of March, 2018 we have organized the second annual GCP training for all our employees and co-workers.

Read more …

First phase study

We have just succesfully finished the second part of the first phase study with no Serious Adverse Events.

Read more …

Bioequivalence study

We have just finished clinical part of one of our ongoing bioequivalence Clinical Studies.

Read more …

Membership in SCRS

We have joined the Society for Clinical Research Sites (SCRS)!

 

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2022 © Bio Research Group. All rights reserved.

 

scroll to top ▲